News
Video
ESA Outcomes by SF3B1 Mutation Status in Lower-Risk MDS
Author(s):
Dr Madanat reviews data from an abstract presented at ASCO 2023 on the outcomes of ESA therapy in patients with SF3B1-mutated lower-risk MDS.
EP: 1.Diagnosing Myelodysplastic Syndromes (MDS)
EP: 2.Risk Stratification of MDS
EP: 3.First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia
EP: 4.Initiating Treatment for Lower-Risk MDS With Symptomatic Anemia
EP: 5.Monitoring Treatment With ESAs for Lower-Risk MDS With Symptomatic Anemia
EP: 6.Second-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia
EP: 7.Patient Profile: A 75-Year-Old Man With Lower-Risk MDS and Symptomatic Anemia
EP: 8.Treatment Approaches for Lower-Risk MDS With Symptomatic Anemia
EP: 9.Patient Profile: A 79-Year-Old Man With Lower-Risk MDS and a KRAS Mutation
EP: 10.Treatment Approaches for Lower-Risk MDS With RAS Mutations
Now Viewing
EP: 11.ESA Outcomes by SF3B1 Mutation Status in Lower-Risk MDS
EP: 12.Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial
EP: 13.Imetelstat for Lower-Risk MDS: Data From the IMerge Trial
EP: 14.Oral HMAs in Lower-Risk MDS Treatment
EP: 15.IRAK1 and IRAK4 Inhibitors for the Treatment of Lower-Risk MDS
EP: 16.Key Trials in the Treatment of Higher-Risk MDS
EP: 17.Final Thoughts on Recent Data Updates in MDS
Related Videos
Related Content
